Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis.

Health Canada's use of expedited approvals was stable over the entire time period. It was unable to reliably predict which drugs will offer major therapeutic gains. The findings in this study should provoke a discussion about whether Health Canada should continue to use these pathways and if so how their use can be improved.